Edesa Biotech, Inc. cotiza a 2.85 USD y tiene una capitalización bursátil de $39M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute res…
| Periodo | 2026-05 | 2026-02 | 2025-12 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.49 | $-0.28 | $-0.32 | $-0.25 |
| Estimado | $-0.26 | $-0.45 | $-0.27 | $-0.26 |
| Sorpresa | -88.5% | +37.8% | -18.5% | +3.8% |
| Métrica | EDSA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -57.7% | -40.4% | -17.3% |
| ROA | -53.1% | -32.0% | -21.1% |
| Current Ratio | 10.67 | 2.84 | +7.83 |
| Debt / Equity | — | 0.28 | — |